Novartis' leading CAR-T cancer therapy gains 'breakthrough' status at the FDA

July 7, 2014 6:50 PM

4 0

The FDA has provided its special 'breakthrough' status for Novartis' ($NVS) closely-watched development program for a personalized CAR-T cancer therapy, promising to help speed development for engineered T cells.

Novartis CEO Joe Jimenez vowed to Forbes recently that he had essentially provided a blank check to the team at the University of Pennsylvania which is developing CTL019. The program relies on adapting T cells with chimeric antigen receptors. Patients' T cells are removed and then genetically modifi...

Read more

To category page